CYP2E1 and hepatocellular carcinoma: Kaplan–Meier analysis revealed that HCC patients with low expression of CYP2E1 demonstrated a lower overall survival compared with those with high expression of CYP2E1 (median survival 21.7 months versus > 40.4 months) (P = 0.0248) (Fig. 1G).